Evidence map›Paper›PMID 38867136›Full record

ArticleRapid communications in mass spectrometry : RCM2025

Development of a high-throughput dual-stream liquid chromatography-tandem mass spectrometry method to screen for inhibitors of glutamate carboxypeptidase II.

Nate Hoxie, Yixuan Qiu, Stephen C Kales, Rick Schneider, Xin Hu, Anu Dalal, Stephanie L Ford-Scheimer, Robyn Wiseman, Takashi Tsukamoto, Huijun Wei and 3 more

Abstract read
In one paragraph

Article in Rapid communications in mass spectrometry : RCM, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Targeting NAAG metabolism restores cognition and synaptic integrity in EcoHIV-infected mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nate HoxieNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Yixuan QiuNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Stephen C KalesNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Rick SchneiderNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Xin HuNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Anu DalalNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Stephanie L Ford-ScheimerNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Robyn WisemanJohns Hopkins Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Takashi TsukamotoJohns Hopkins Drug Discovery and Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Huijun WeiJohns Hopkins Drug Discovery and Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Barbara S SlusherJohns Hopkins Drug Discovery and Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
John S JaniszewskiNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
Matthew D HallNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.

Funding

Research Services Section (RSS)ZICTR000242 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI WILSON, KELLI · 2015 to 2025
$64.9M
Development of A Specialized Platform for Innovative Research Exploration (ASPIRE)ZICTR000438 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI WILSON, KELLI · 2022 to 2025
$25.2M
Targeting glutamate carboxypeptidase in perinatal brain injuryR01NS093416 · NINDS · JOHNS HOPKINS UNIVERSITY · PI Sujatha Kannan, Kannan Rangaramanujam · 2016 to 2026
$4.8M
Pharmacology and Molecular Sciences Training Program: Enhancing Inclusivity Through Universal Design for Learning in Graduate CoursesT32GM135083 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Caren L. Freel Meyers · 2020 to 2026
$3.3M
Intramural NIH HHS Z99 TR999999NIGMS NIH HHS T32 GM135083NIH HHSNINDS NIH HHS R01 NS093416
6 · The paper itself

Abstract

rationaleGlutamate carboxypeptidase II (GCPII) catalyzes the hydrolysis of N-acetylaspartylglutamate (NAAG) to yield glutamate (Glu) and N-acetylaspartate (NAA). Inhibition of GCPII has been shown to remediate the neurotoxicity of excess Glu in a variety of cell and animal disease models. A robust high-throughput liquid chromatography-tandem mass spectrometry (LC/MS/MS) method was needed to quantify GCPII enzymatic activity in a biochemical high-throughput screening assay.

methodsA dual-stream LC/MS/MS method was developed. Two parallel eluent streams ran identical HILIC gradient methods on BEH-Amide (2 × 30 mm) columns. Each LC channel was run independently, and the cycle time was 2 min per channel. Overall throughput was 1 min per sample for the dual-channel integrated system. Multiply injected acquisition files were split during data review, and batch metadata were automatically paired with raw data during the review process.

resultsTwo LC sorbents, BEH-Amide and Penta-HILIC, were tested to separate the NAAG cleavage product Glu from isobaric interference and ion suppressants in the bioassay matrix. Early elution of NAAG and NAA on BEH-Amide allowed interfering species to be diverted to waste. The limit of quantification was 0.1 pmol for Glu. The Z-factor of this assay averaged 0.85. Over 36 000 compounds were screened using this method.

conclusionsA fast gradient dual-stream LC/MS/MS method for Glu quantification in GCPII biochemical screening assay samples was developed and validated. HILIC separation chemistry offers robust performance and unique selectivity for targeted positive mode quantification of Glu, NAA, and NAAG.

Indexed as

Enzyme InhibitorsGlutamate Carboxypeptidase IIHigh-Throughput Screening AssaysTandem Mass SpectrometryChromatography, LiquidDipeptidesHumansReproducibility of ResultsDipeptidesEnzyme InhibitorsGlutamate Carboxypeptidase IIisospaglumic acid

Identifiers

PMID38867136
PMCPMC11737842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.